DeepHealth’s AI for breast ultrasound lesion detection cleared by FDA

FDA cleared DeepHealth's AI for breast ultrasound that automates lesion detection and reporting. Validated with 16 radiologists, it aims to standardize workflows and is now commercially available and eligible for reimbursement.

• RadNet plans to implement the solution across its network of 440 centers by the end of the year.
• The product is eligible for reimbursement under an existing Category 3 CPT code for quantitative ultrasound tissue characterization.
• DeepHealth's breast platform now includes AI applications for mammography, ultrasound, density assessment, breast arterial calcification classification, risk prediction, and quality analytics.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.